SG11201407412QA - Method of prevention of neurological diseases - Google Patents

Method of prevention of neurological diseases

Info

Publication number
SG11201407412QA
SG11201407412QA SG11201407412QA SG11201407412QA SG11201407412QA SG 11201407412Q A SG11201407412Q A SG 11201407412QA SG 11201407412Q A SG11201407412Q A SG 11201407412QA SG 11201407412Q A SG11201407412Q A SG 11201407412QA SG 11201407412Q A SG11201407412Q A SG 11201407412QA
Authority
SG
Singapore
Prior art keywords
international
drive
priestly
carlsbad
rule
Prior art date
Application number
SG11201407412QA
Other languages
English (en)
Inventor
Rodolfo Gonzalez
Ibon Garitaonandia
Ruslan Semechkin
Original Assignee
Int Stem Cell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Stem Cell Corp filed Critical Int Stem Cell Corp
Publication of SG11201407412QA publication Critical patent/SG11201407412QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11201407412QA 2012-06-05 2013-06-03 Method of prevention of neurological diseases SG11201407412QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261655742P 2012-06-05 2012-06-05
PCT/US2013/043927 WO2013184591A1 (en) 2012-06-05 2013-06-03 Method of prevention of neurological diseases

Publications (1)

Publication Number Publication Date
SG11201407412QA true SG11201407412QA (en) 2014-12-30

Family

ID=49712532

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407412QA SG11201407412QA (en) 2012-06-05 2013-06-03 Method of prevention of neurological diseases

Country Status (13)

Country Link
US (1) US10258632B2 (ko)
EP (1) EP2841060A4 (ko)
JP (1) JP2015518887A (ko)
KR (1) KR20150023292A (ko)
CN (1) CN104379136A (ko)
AU (1) AU2013271841B2 (ko)
CA (1) CA2875330A1 (ko)
HK (1) HK1201741A1 (ko)
IL (1) IL235736B (ko)
MX (1) MX2014014993A (ko)
RU (1) RU2014153894A (ko)
SG (1) SG11201407412QA (ko)
WO (1) WO2013184591A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3055548B1 (fr) 2016-09-05 2018-09-28 Metabrain Research Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
CN106265685A (zh) * 2016-09-18 2017-01-04 南通大学 没药甾酮z在制备抗抑郁症药物中的应用
CN109223785A (zh) * 2018-10-29 2019-01-18 中国药科大学 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用
EP3659593A1 (en) * 2018-11-30 2020-06-03 Forschungszentrum Jülich GmbH/ Abteilung RP-PT Trmt2a inhibitors for use in the treatment of polyglutamine diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002193818A (ja) * 2000-12-22 2002-07-10 Council Scient Ind Res ググリピッドの新規使用法:認知エンハンサー、抗高血糖性の、及び皮膚の状態に関するものとして
KR101166000B1 (ko) * 2002-01-28 2012-07-16 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
WO2006024947A2 (en) 2004-09-02 2006-03-09 Neuro Therapeutics Ab Methods and materials relating to enhanced production of dopamine neurons
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
WO2010088400A1 (en) 2009-01-28 2010-08-05 Catholic Healthcare West Methods of diagnosing and treating neurodegenerative diseases

Also Published As

Publication number Publication date
RU2014153894A (ru) 2016-08-10
US10258632B2 (en) 2019-04-16
HK1201741A1 (en) 2015-09-11
AU2013271841B2 (en) 2018-03-08
IL235736A0 (en) 2015-01-29
CA2875330A1 (en) 2013-12-12
CN104379136A (zh) 2015-02-25
MX2014014993A (es) 2015-06-17
KR20150023292A (ko) 2015-03-05
JP2015518887A (ja) 2015-07-06
IL235736B (en) 2020-06-30
EP2841060A4 (en) 2016-02-24
US20150094289A1 (en) 2015-04-02
AU2013271841A1 (en) 2014-11-27
WO2013184591A1 (en) 2013-12-12
EP2841060A1 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201408124PA (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
SG11201804936UA (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201407200TA (en) Liquid formulation
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201804885TA (en) Monomaleimide-functionalized platinum compounds for cancer therapy